CY1106541T1 - Φαρμακευτικη συνθεση και χρηση r-nsaid για αντιμετωπιση φλεγμονης - Google Patents

Φαρμακευτικη συνθεση και χρηση r-nsaid για αντιμετωπιση φλεγμονης

Info

Publication number
CY1106541T1
CY1106541T1 CY20071100559T CY071100559T CY1106541T1 CY 1106541 T1 CY1106541 T1 CY 1106541T1 CY 20071100559 T CY20071100559 T CY 20071100559T CY 071100559 T CY071100559 T CY 071100559T CY 1106541 T1 CY1106541 T1 CY 1106541T1
Authority
CY
Cyprus
Prior art keywords
cox
nsaid
mrna
synthesis
nsaids
Prior art date
Application number
CY20071100559T
Other languages
English (en)
Inventor
William J. Wechter
Original Assignee
Loma Linda University Medical Centre
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22517175&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1106541(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Loma Linda University Medical Centre filed Critical Loma Linda University Medical Centre
Publication of CY1106541T1 publication Critical patent/CY1106541T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/402—1-aryl substituted, e.g. piretanide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

Η παρούσα εφεύρεση σχετίζεται με φαρμακευτικές συνθέσεις οι οποίες περιλαμβάνουν εναντιομερικώς καθαρά R-NSAIDs και τις μεθόδους της χρήσης τους για την αντιμετώπιση φλεγμονής. Κατά προτίμηση, το R-NSAID που χρησιμοποιείται είναι η R-φλουρβιπροφένη η οποία χορηγείται σε μια δόση τουλάχιστον 2.5 χιλιοστογραμμαρίων ανά χιλιόγραμμο σωματικού βάρους ανά ημέρα. Η αντιφλεγμονώδης δράση των R-NSAIDs οφείλεται στην ικανότητα τους να παρεμβαίνουν στη βιοσύνθεση της COX-2 αναστέλλοντας τη σύνθεση του COX-2 mRNA, παρά παρεμποδίζοντας μόνο τη δράση του ενζύμου αυτού καθαυτού. Για να επιτευχθεί η αναστολή της σύνθεσης του COX-2 mRNA, το R-NSAID πρέπει να υπάρχει σε σχετικά υψηλές δόσεις. Επειδή το R-NSAID είναι εκλεκτικό στη δράση του, ήτοι δεν αναστέλλει είτε την σύνθεση του COX-1 mRNA είτε του COX-1 ενζύμου αυτού καθαυτού, μπορεί να χορηγηθεί στις απαιτούμενες υψηλές δόσεις επειδή οι ιστο-προστατευτικές επιδράσεις των προσταγλανδινών που φτιάχνονται μέσω του COX-1 μονοπατιού δεν υφίστανται παρέμβαση.
CY20071100559T 1998-09-03 2007-04-26 Φαρμακευτικη συνθεση και χρηση r-nsaid για αντιμετωπιση φλεγμονης CY1106541T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14639598A 1998-09-03 1998-09-03
PCT/US1999/020261 WO2000013684A2 (en) 1998-09-03 1999-09-03 Pharmaceutical composition and method for treatment of inflammation

Publications (1)

Publication Number Publication Date
CY1106541T1 true CY1106541T1 (el) 2012-01-25

Family

ID=22517175

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071100559T CY1106541T1 (el) 1998-09-03 2007-04-26 Φαρμακευτικη συνθεση και χρηση r-nsaid για αντιμετωπιση φλεγμονης

Country Status (13)

Country Link
US (1) US6472433B2 (el)
EP (1) EP1143958B8 (el)
JP (1) JP2002524415A (el)
CN (1) CN1391470A (el)
AT (1) ATE353010T1 (el)
AU (1) AU6026099A (el)
CA (1) CA2342628C (el)
CY (1) CY1106541T1 (el)
DE (1) DE69933049T2 (el)
DK (1) DK1143958T3 (el)
ES (1) ES2281981T3 (el)
PT (1) PT1143958E (el)
WO (1) WO2000013684A2 (el)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020048596A1 (en) * 1994-12-30 2002-04-25 Gregor Cevc Preparation for the transport of an active substance across barriers
DE69825495T2 (de) 1998-12-23 2005-07-28 Idea Ag Verbesserte formulierung zur topischen, nichtinvasiven anwendung in vivo
PT1031346E (pt) 1999-01-27 2002-09-30 Idea Ag Vacinacao nao invasiva atraves da pele
ES2173679T3 (es) 1999-01-27 2002-10-16 Idea Ag Inmunizacion/transporte transnasal con vehiculos altamente adaptables.
DE19907895A1 (de) * 1999-02-24 2000-11-16 Paz Arzneimittelentwicklung Verwendung von R-Arylpropionsäuren zur Herstellung von Arzneimitteln zur Behandlung von Erkrankungen bei Mensch und Tier, welche durch die Hemmung der Aktivierung von NF-kB therapeutisch beeinflußt werden können
MXPA02000053A (es) 1999-07-05 2003-07-21 Idea Ag Un metodo para mejorar el tratamiento a traves de barreras adaptables semipermeables.
US20060004086A1 (en) * 2000-04-13 2006-01-05 Mayo Foundation For Medical Education And Research Method of reducing Abeta42 and treating diseases
EP1284729A4 (en) * 2000-04-13 2007-12-19 Mayo Foundation REDUCTION AGENTS OF A (BETA) 42
DE10047319A1 (de) * 2000-09-25 2002-04-18 Paz Arzneimittelentwicklung Verwendung von R-Arylpropionsäuren zur Herstellung von Arzneimitteln zur Behandlung von Erkrankungen, welche durch die Hemmung der Aktivierung des nukleären Transkriptionsfaktors AP-1 therapeutisch beeinflußt werden können
US20040077604A1 (en) 2001-12-19 2004-04-22 Lenard Lichtenberger Method and compositions employing formulations of lecithin oils and nsaids for protecting the gastrointestinal tract and providingenhanced therapeutic activity
US20030027867A1 (en) * 2001-06-29 2003-02-06 Myriad Genetics, Incorporated Use of R-NSAID compounds for anti-HIV treatment
US20030143165A1 (en) * 2002-01-25 2003-07-31 Allan Evans NSAID-containing topical formulations that demonstrate chemopreventive activity
US20040105881A1 (en) * 2002-10-11 2004-06-03 Gregor Cevc Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin
WO2004071431A2 (en) * 2003-02-05 2004-08-26 Myriad Genetics, Inc. Method and composition for treating neurodegenerative disorders
US20050042284A1 (en) * 2003-07-11 2005-02-24 Myriad Genetics, Incorporated Pharmaceutical methods, dosing regimes and dosage forms for the treatment of Alzheimer's disease
WO2006050926A2 (en) * 2004-11-12 2006-05-18 Idea Ag Extended surface aggregates in the treatment of skin conditions
CA2615063A1 (en) * 2005-07-22 2007-02-01 Myriad Genetics, Inc. High drug load formulations and dosage forms
US9125899B1 (en) 2010-06-17 2015-09-08 Stc.Unm Modulators of GTPases and their use
EP2468270A1 (en) 2010-12-21 2012-06-27 GALENpharma GmbH (R)-2-(3-fluoro-4-phenylphenyl)propionic acid for use in the treatment of skin diseases
EP2768499A4 (en) 2011-10-17 2015-08-26 Univ Vanderbilt INDOMETACIN ANALOGUES FOR THE TREATMENT OF CANCER PROSTATE RESISTANT TO CASTRATION
US20150183737A1 (en) * 2012-07-20 2015-07-02 Vanderbilt University Compositions and methods for substrate-selective inhibition of endocannabinoid oxygenation
US9012402B1 (en) 2014-06-11 2015-04-21 James Blanchard Gel for topical delivery of NSAIDs to provide relief of musculoskeletal pain and methods for its preparation
US10821075B1 (en) 2017-07-12 2020-11-03 James Blanchard Compositions for topical application of a medicaments onto a mammalian body surface
CN113712960B (zh) * 2021-09-23 2023-04-07 南京医科大学 R-酮咯酸在防治主动脉夹层和主动脉瘤中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4028906A1 (de) 1990-09-12 1992-03-19 Paz Arzneimittelentwicklung Arzneimittel sowie deren herstellung und deren verwendung bei der bekaempfung von schmerzen und/oder entzuendungen und/oder fieber an tieren und menschen
US5331000A (en) * 1992-03-09 1994-07-19 Sepracor Inc. Antipyretic and analgesic methods and compositions containing optically pure R(-) ketoprofen
DE4319438C1 (de) * 1993-06-11 1994-06-01 Gerd Dr Dr Geislinger Arzneimittel auf der Grundlage von Ketoprofen zur Bekämpfung von Schmerzen und/oder Entzündungen und/oder Fieber an Menschen und Tieren
US6160018A (en) * 1995-03-13 2000-12-12 Loma Linda University Medical Center Prophylactic composition and method for alzheimer's Disease
IT1298214B1 (it) * 1998-01-28 1999-12-20 Dompe Spa Sali dell'acido (r) 2-(3-benzoilfenil) propionico e loro composizioni farmaceutiche.

Also Published As

Publication number Publication date
JP2002524415A (ja) 2002-08-06
ATE353010T1 (de) 2007-02-15
DE69933049T2 (de) 2007-10-04
DE69933049D1 (de) 2006-10-12
ES2281981T3 (es) 2007-10-01
US20010012849A1 (en) 2001-08-09
EP1143958B8 (en) 2007-05-23
EP1143958B1 (en) 2007-01-31
PT1143958E (pt) 2007-04-30
WO2000013684A2 (en) 2000-03-16
WO2000013684A3 (en) 2002-05-30
DK1143958T3 (da) 2007-04-10
CA2342628A1 (en) 2000-03-16
US6472433B2 (en) 2002-10-29
CN1391470A (zh) 2003-01-15
EP1143958A2 (en) 2001-10-17
EP1143958A3 (en) 2002-08-21
AU6026099A (en) 2000-03-27
CA2342628C (en) 2009-07-07

Similar Documents

Publication Publication Date Title
CY1106541T1 (el) Φαρμακευτικη συνθεση και χρηση r-nsaid για αντιμετωπιση φλεγμονης
MX9308199A (es) Inhibidores de enzima.
ES2172654T3 (es) Uso de nsaid para el tratamiento de carcinomas de celulas escamosas de la cavidad oral u orofaringe.
NO954878L (no) Pyrrolderivater
BRPI0411319A (pt) compostos terapeuticamente ativos e sua utilização
DE69824622D1 (de) Verwendung von vitamin d derivaten zur verstärkung der wirkung von zytotoxischen stoffen
AR021858A1 (es) Composicion de liberacion modificada de particulas multiples
TR199801530T2 (xx) VEGF �nhibit�rleri olarak kinazolin t�revleri.
YU49026B (sh) UPOTREBA 17 Гџ -(N-TERC-BUTILKARBAMOIL)-4-AZA-5-ALFA-ANDROST-1-3-ON ZA PROIZVODNJU LEKA ZA TRETIRANJE ANDROGENE ALOPECIJE
ATE205494T1 (de) Pyridylfuran- und pyridylthiphenderivate und deren pharmazeutische verwendung
ES2176502T3 (es) Derivados de hidroxilamina utiles para mejorar la pproduccion de chaperonas moleculares su su preparacion.
BR0308222A (pt) Terapias de combinação para tratar células deficientes em metiltioadenosina fosforilase
BR9810520A (pt) Inibidor do fator xa isolado ou em combinação com um anti-agregador plaquetário, contra a trambose arterial
DE69710065T2 (de) Androsten-derivate
NO20033665L (no) Azoler som malonyl-CoA-dekarboksylaseinhibitorer som er anvendbare som metaboliske modulatorer
BR9709838A (pt) Regime de administração que fornece um perfil de plasma no sangue de um inibidor de h+,k+-atpase composição farmacêutica oral uso da mesma e de inibidor h+,k+-atpase e processos para melhorar a inibição de secreção de ácido gástrico e o efeito terapêutico no tratamento de perturbações gastrintestinais e para receber um perfil estendido de plasma de um inibidor de h+,k+-atpase
DK599789A (da) 3,5-di-tertiaer-butyl-4-hydroxyphenyl-1,3,4-thiadazoler og -oxadiazoler samt 3,5-di-tertiaer-butyl-4-hydroxyphenyl-1,2,4-thiadazoler, -oxadiazoler og -triazoler som anti-inflammatoriske midler
Atkinson et al. Prodrug activation gene therapy and external beam irradiation in the treatment of prostate cancer
CO5190674A1 (es) Tratamiento de desordenes neuroticos desordenes neuroticos
DE59911734D1 (de) Kombination von selen-haltigen verbindungen mit gemcitabin oder mitomycin c
BR9910678A (pt) Composto, composição farmacêutica, método para traramento ou prevenção de uma doença inflamatória, método para tratamento de uma condição ou uma doença mediada por mmps, tnf, agrecanase, ou um composto dos mesmos, em um mamìfero, método de redução de nìveis de tnf em pacientes, sem a inibição de mmps, método para tratamento de uma condição ou uma doença e uso de um novo composto
IT1276162B1 (it) Geranilgeranil-derivati,procedimento per la loro preparazione e relative composizioni farmaceutiche
DK0814792T3 (da) Mercapto- og selenderivater som inhibitorer af nitritoxidsyntase
NO985676D0 (no) Forbindelser med colchicinstruktur, deres anvendelse som legemidler og blandinger som inneholder dem
ITMI922742A0 (it) Composti ad attivita' terapeutica utili per il trattamento di malattieconnesse ad una carenza di glutatione, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono.